Research programme: small molecule oncology therapeutics - AVEO/OSI Pharmaceuticals
Alternative Names: OSI-296Latest Information Update: 04 Dec 2023
At a glance
- Originator AVEO Pharmaceuticals; OSI Pharmaceuticals
- Developer Astellas Pharma
- Class Small molecules
- Mechanism of Action Emt protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 01 Aug 2013 Preclinical development is ongoing in USA
- 29 May 2012 AVEO Pharmaceuticals is now called AVEO Oncology